Author name: Faisal Almesfer

New Zealand neuroscience company Exsurgo has appointed experienced senior engineering executive, Jiva Muthu as Chief Operating Officer.  Muthu joins Exsurgo from Rakon – one of the world’s largest manufacturers of frequency control products and timing solutions – and has 18 years’ experience in the medical devices industry with Fisher & Paykel Healthcare, Rex Bionics and […]

At Exsurgo, our vision is to unlock the power of neuroscience to ease suffering and enhance human potential. We’re on a mission to transform the way the world treats neurological problems with effective, accessible and non-pharmaceutical solutions that harness the latest in science, technology, engineering and big data.  It’s a lofty goal, but a recent

A recent UK study has confirmed the exciting potential of a breakthrough treatment for chronic pain management developed by neuroscience company, Exsurgo. Chronic pain (defined as pain that persists for longer than three months) affects up to 1 in 5 people around the world and is a massive burden on healthcare systems and economies. Chronic

Newshub, one of New Zealand’s biggest news services, has reported on the potential of Exsurgo’s Axon technology to help treat chronic pain and shared the results of a proof-of-concept trial in the UK. As Laura Tupou’s story said: The answer to chronic pain management could be to retrain your brain. A Kiwi company has designed

In a new study, researchers have found that the prevalence of chronic pain is increasing for all demographics of U.S. adults. The research, which appears in the journal Demography, highlights that the prevalence of chronic pain has increased the most for people from lower socioeconomic backgrounds. “We looked at the data from every available perspective, including

The Guardian has reported on a significant change to guidelines for pain treatment from the UK’s National Institute for Health and Care Excellence, which say that doctors “should advise sufferers to use physical and psychological therapies rather than analgesics to manage their pain”. There is “little or no evidence” that treating the condition with painkillers makes any difference to the person’s

Exsurgo has appointed experienced financial executive John Emson as its first Chief Financial Officer. Emson, who has spent over 30 years in finance and M&A across the technology, manufacturing, health and education sectors, has been working closely with Exsurgo co-founder Richard Little as an advisor to the company since last year. Exsurgo is developing technologies

Background: As many as 80% of stroke survivors experience upper limb (UL) disability. The strong relationships between disability, lost productivity, and ongoing healthcare costs mean reducing disability after stroke is critical at both individual and society levels. Unfortunately, the amount of UL-focused rehabilitation received by people with stroke is extremely low. Activity monitoring and promotion

Exsurgo has begun a potentially ground-breaking UK-based clinical trial to determine the effectiveness of Axon, a user-friendly neurofeedback product that treats the primary and secondary symptoms of chronic pain without the use of pharmaceuticals. Exsurgo is a team of multi-disciplinary professionals in New Zealand and the UK who engineer products that ease human suffering and